Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhaled Medications01:23

Inhaled Medications

237
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
237
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

233
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
233
Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
2.5K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

218
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
218
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

3.0K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
3.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeted self-directed learning can support clinicians to improve patient adherence to inhaled corticosteroid therapy in asthma.

BMJ open respiratory research·2025
Same author

Plain language summary of the SHAMAL study in patients with severe eosinophilic asthma treated with benralizumab.

Immunotherapy·2025
Same author

Clinical Accuracy and Risk of Harm in Asthma-Related Content on TikTok.

Chest·2024
Same author

Long-Term Effectiveness of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis.

The journal of allergy and clinical immunology. In practice·2024
Same author

The role of the clinical pharmacist in the respiratory or sleep multidisciplinary team.

Breathe (Sheffield, England)·2023
Same author

Diagnosing and managing pleural disease.

Breathe (Sheffield, England)·2023
Same journal

A hypermetabolic pulmonary lesion in a patient with breast cancer.

Breathe (Sheffield, England)·2026
Same journal

Rigid bronchoscopy is the gold standard management of inhaled foreign bodies in children: myth or maxim?

Breathe (Sheffield, England)·2026
Same journal

The price of immune awakening: bridging knowledge gaps in checkpoint inhibitor-related pneumonitis in lung cancer.

Breathe (Sheffield, England)·2026
Same journal

Where are we with biomarkers in paediatric asthma in 2026?

Breathe (Sheffield, England)·2026
Same journal

Recurrent invasive fungal infection with locally advanced thymoma: diagnostic challenges in complex mediastinal disease.

Breathe (Sheffield, England)·2026
Same journal

Elevated <i>D</i> <sub>LCO</sub> and pulmonary function evolution during treatment in a patient with hyperleukocytosis and leukostasis.

Breathe (Sheffield, England)·2026
See all related articles

Related Experiment Video

Updated: Jun 5, 2025

Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation
09:42

Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation

Published on: November 8, 2013

13.5K

Does inhaler adherence really matter in severe asthma?

Gráinne d'Ancona1,2, Brian D Kent3,4

  • 1Guy's and St Thomas' NHS Foundation Trust, London, UK.

Breathe (Sheffield, England)
|December 11, 2024
PubMed
Summary
This summary is machine-generated.

Inhaled corticosteroids (ICS) are standard asthma treatments, but some severe asthma patients show resistance. This review questions demanding adherence to ICS for those unresponsive to this therapy.

More Related Videos

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

31.8K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.6K

Related Experiment Videos

Last Updated: Jun 5, 2025

Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation
09:42

Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation

Published on: November 8, 2013

13.5K
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

31.8K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.6K

Area of Science:

  • Pulmonology
  • Respiratory Medicine
  • Clinical Therapeutics

Background:

  • Inhaled corticosteroids (ICS) have been the primary treatment for asthma since the 1960s.
  • ICS therapies effectively reduce asthma symptoms, complications, and mortality.
  • Despite ICS use, a subset of patients exhibits severe, uncontrolled asthma.

Purpose of the Study:

  • To review the efficacy and appropriateness of demanding adherence to inhaled corticosteroid (ICS) therapy.
  • To examine treatment resistance in severe asthma patients.
  • To discuss alternative approaches for managing severe, ICS-resistant asthma.

Main Methods:

  • Literature review of studies on inhaled corticosteroid (ICS) efficacy in asthma.
  • Analysis of severe asthma definitions and treatment adherence challenges.
  • Discussion of clinical evidence regarding ICS resistance in specific patient cohorts.

Main Results:

  • High-dose ICS therapies are not universally effective for all severe asthma patients.
  • A significant group of severe asthma patients demonstrates resistance to ICS treatments.
  • Current adherence demands may be inappropriate for ICS-resistant individuals.

Conclusions:

  • The effectiveness of inhaled corticosteroid (ICS) therapy varies among severe asthma patients.
  • Treatment adherence should be critically evaluated in severe asthma cohorts resistant to ICS.
  • Further research into alternative therapies for ICS-resistant severe asthma is warranted.